ArticleMaterials today. Bio2026
Hyaluronic acid engineered melanin-MOF nanoreactor synergistically remodeling redox and immune homeostasis for targeted acute lung injury therapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS)-triggered oxidative stress, inflammatory responses, and overactivation of immune cells are critical factors exacerbating acute lung injury (ALI). Conventional clinical therapies are often limited by non-specificity, single-target limitations, and significant side effects to precisely modulate the complex pathological microenvironment. Here, we designed a hyaluronic acid-engineered nanoreactor (HA@MZ) through in situ encapsulation of melanin (MA) within ZIF-67, allowing multi-target synergistic therapy of ALI. The HA coating facilitates mucus penetration and targeted accumulation in injured lungs, exhibiting good biocompatibility. Under acidic inflammatory conditions, HA@MZ responsively releases MA, which efficiently scavenges ROS. This process activates Nrf2/HO-1 and GPX4 pathways while inhibiting NF-κB driven inflammation and M1 macrophage polarization, leading to reduced lipid peroxidation and recovery of redox and immune balance. Both in vitro and in vivo results confirm the lung microenvironment-balancing capacity of HA@MZ, offering a promising nanotherapeutic strategy for ALI and other inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.